CCND2 and lung adenocarcinoma: Further analysis of the methylation patterns of other cancer types revealed that the CCND2 promoter hypermethylation was significant in breast cancer, lung adenocarcinoma, and liver cancer (Figure 2C,E, Table 1 and Table S4), but not in esophageal and colon cancers (Figure 2F,G and Table 1).